White paperThe Enterprise Framework for Compliant, Scalable AI
Download now

AI Deployment & Workflow

AI Agents for Regulated Workflows

AI delivers value when agents are embedded in real work. USDM helps regulated teams deploy AI into intake triage, drafting, review, knowledge retrieval, evidence capture, and exception handling so work moves faster across Quality, Regulatory, Clinical, Manufacturing, Commercial/Medical, and IT/Ops.

AI in life sciences · life sciences AI consulting · AI consulting for pharma and biotech

Life Sciences AI Strategy Starts with a Compliant Foundation

AI in life sciences delivers value when strategy, implementation, and compliance move together. From AI readiness assessments and governance models to audit-ready deployment frameworks, USDM brings the consulting depth regulated organizations need to operationalize AI with confidence. Across pharma, biotech, and broader GxP environments, USDM connects AI strategy to practical implementation, helping teams accelerate innovation without losing control of risk, quality, or regulatory alignment.

AI governance life sciences · regulated AI · AI validation

AI Governance for Compliant, Scalable Life Sciences AI

AI adoption in life sciences now depends on governance that can withstand regulatory scrutiny, platform change, and operational scale. This white paper outlines an enterprise framework for compliant AI, covering lifecycle oversight, vendor risk, validated AI systems, and governance in GxP environments. USDM brings together AI strategy, regulatory depth, and digital trust expertise to support scalable, inspection-ready AI programs.

AI for quality, regulatory, PV, clinical, validation, CAPA, and deviation management

47 Applied AI Use Cases for Life Sciences Teams

AI in life sciences gets real when it solves operational bottlenecks across quality, regulatory, clinical, manufacturing, and pharmacovigilance. This white paper outlines 47 applied AI use cases designed for regulated environments, with measurable impact and inspection-aware architecture. USDM combines domain expertise, digital quality strategy, and practical deployment thinking to help organizations identify where AI can deliver value fastest and scale responsibly.

trusted AI · responsible AI · AI risk management · explainable AI

AI Oversight Starts After Validation

Validating an AI system for a GxP-regulated environment is only the first step. As models evolve, data shifts, and regulations change, life sciences companies need a way to maintain compliance after deployment. USDM brings the regulatory depth, technology expertise, and digital quality approach needed to support continuous verification, strengthen AI oversight, and keep regulated organizations inspection ready as AI scales.

Recent AI resources

Fresh thinking for governed AI deployment.

The newest USDM resources from the last 45 days covering AI readiness, agentic workflows, Claude governance, enterprise knowledge, and the controls needed to deploy AI in regulated life sciences work.

Blog

Where Glean Fits in the Enterprise AI Stack

A practical look at how Glean fits into the enterprise AI ecosystem as a governed work AI layer across knowledge, permissions, assistants, agents, and workflows.

Read resource
Blog

AI Governance Is No Longer Just a Technology Problem

AI is becoming an operational dependency for life sciences organizations. Brian Rankin explains why governance maturity, concentration-risk oversight, and executive accountability need to evolve with adoption.

Read resource
Blog

Trusted to Do Their Part: The Future of USDM Cloud Assurance

The USDM Cloud Assurance team explains how continuous evidence, attestable reasoning, calibrated autonomy, and human attestation shape trust for AI-bearing regulated software.

Read resource
Blog

90-Day AI Readiness for Life Sciences

A 90-day AI readiness assessment for life sciences: inventory use cases, classify risk, map data and platform controls, select pilots, and build a governed adoption roadmap.

Read resource
Blog

Agents in GxP Workflows: How to Govern Claude Without Freezing Innovation

Learn how life sciences organizations can govern Claude-powered agents in GxP workflows with bounded autonomy, validation planning, audit evidence, and human oversight without slowing AI innovation.

Read resource
Blog

Claude for Life Sciences Regulated Workflows

USDM explains how Anthropic Claude can support regulated life sciences workflows when teams define intended use, governed context, human review, validation, and inspection-ready evidence.

Read resource
Blog

Claude Cowork for Life Sciences: From Chatbot to Governed Work Partner

USDM explains how life sciences teams can evaluate Claude Cowork as a governed work partner, not an unmanaged chatbot, with clear intended use, human review, and audit-ready controls.

Read resource
Blog

Claude in GxP AI Governance and Validation

A practical USDM framework for Claude GxP validation: intended use, risk classification, data controls, human review, testing, monitoring, and change control for regulated AI adoption.

Read resource
Blog

Human-in-the-Loop Claude Prompts for Regulated Teams

Prompt patterns for regulated life sciences teams using Claude: frame intended use, ground responses in approved sources, require uncertainty handling, and preserve human review evidence.

Read resource
Blog

Layer 0-5: A Life Sciences Operating Model for Claude Adoption

A six-layer operating model for adopting Claude in regulated life sciences — from intended use and governed context through connectors, skills, agents, and evidence-based governance. Start with structure, not demos.

Read resource
Blog

MCP, Connectors, and Skills: The New Integration Layer for Regulated AI

Learn how life sciences teams can govern MCP, Claude connectors, and Skills as a regulated AI integration layer with access controls, validation evidence, and change management.

Read resource
Blog

Citizen Development at AI Speed: Governance Risks for Life Sciences

AI-assisted citizen development can bypass governance controls. Learn the cybersecurity, validation, and data risks life sciences organizations need to manage.

Read resource
Blog

Work AI for Life Sciences: Why USDM Chose Glean

Why USDM chose Glean as a Work AI partner for life sciences — enterprise search, permission-aware knowledge, governed connectors, and a practical path from AI intent to regulated impact.

Read resource
Blog

Data Integration & Interoperability in Life Sciences: How to Build a Connected, Compliant Data Ecosystem

Learn why data integration and interoperability are critical in life sciences, and how connected, standards-aligned data improves compliance, speed, visibility, and AI readiness.

Read resource

Frequently Asked Questions

Questions leaders ask before they move.

What is AI strategy in life sciences, and why does it matter now?

AI strategy is the structured plan for identifying, governing, implementing, and scaling AI in regulated environments. It matters because AI is already embedded in platforms and workflows, and unmanaged adoption is harder to govern or defend.

Why do pharma and biotech companies need specialized AI consulting?

Regulated AI initiatives must align with GxP expectations, validation requirements, data governance standards, and evolving global regulations. Specialized consulting combines technical deployment with life sciences compliance and operational reality.

What should executives look for in a life sciences AI consulting partner?

Executives should look for AI expertise plus deep life sciences domain knowledge, including regulated systems, data integrity, quality operations, validation, enterprise change management, readiness assessment, governance, and implementation support.

How do life sciences organizations move from AI strategy to AI implementation?

They prioritize use cases by value, system readiness, data readiness, and governance requirements, then move through readiness assessment, governance definition, focused pilots, validation of results, and scaled workflow deployment.

What are the biggest risks of AI implementation in regulated life sciences environments?

Major risks include poor governance, unclear intended use, weak data controls, lack of validation planning, vendor overreliance, model drift, explainability gaps, auditability gaps, and unclear accountability.

How can executives measure success from life sciences AI consulting and implementation?

Success should be measured through business and compliance outcomes: reduced cycle times, lower compliance costs, faster decisions, stronger inspection readiness, clearer AI ownership, better governance maturity, and scalable operations.

Why does AI strategy need to end in workflow design?

AI strategy only creates value when it turns into controlled workflows teams can actually use. The work has to connect business priorities, process design, change management, data readiness, and deployment planning.

What good AI consulting looks like in pharma and biotech?

Good consulting combines domain knowledge, regulatory awareness, workflow redesign, and validated systems so AI deployment improves execution without breaking compliance.

What does regulated AI require?

When AI influences quality, regulatory, clinical, or manufacturing work, organizations need controls around inputs, outputs, review, traceability, and change so the workflow remains governed and defensible.

How do you keep AI trustworthy after deployment?

Trust comes from visibility, review discipline, and continuous oversight. Teams need clear intervention points, documented exception handling, and monitoring that shows the workflow still behaves as intended over time.